Petrelintide + enicepatide
Roche / Zealand Pharma
Amylin plus GIP/GLP-1 combination tested against components.
Results availability
No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.
Mechanism at a glance
Obesity stage by formulation
Latest: Zealand announced initiation of ZYNERGY on November 18, 2026. The 40-week trial compares three regimens of once-weekly petrelintide plus enicepatide with each component alone and placebo.
Next: Week-40 body-weight change, safety and tolerability.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Related conditions and outcomes
Phase 2 studies1 record
ZYNERGY
Combination developmentAdults with obesity or overweight with a weight-related complication. Zealand announced initiation November 18. The latest registry posting, November 3, lists an estimated November 30 start and estimated enrollment of 486. The sponsor did not report a first dose date.
